Background-Reliable predictive biomarkers are required to address the challenge of disease recurrence following thyroid cancer surgery. We assessed the association of cellular-and serumbased immunologic mediators with thyroid cancer recurrence.
Introduction
Thyroid cancer is the most common endocrine cancer worldwide and among the fastest growing malignancies in the US. Greater understanding of thyroid cancer biology is necessary because of the increasing incidence of this cancer in the last 2 decades. 1 Although most thyroid cancers have an excellent prognosis with a 10-year survival rate of 80-90%, disease recurrence following potentially curative surgery remains a problem that is difficult to predict. 2 Approximately 10-20% of patients develop multiple recurrences, which carry a worse overall prognosis especially when associated with distant metastasis. 3 Thyroglobulin is a biomarker secreted by the cancer cells but is inadequate for surveillance prior to cancer recurrence. This is due to significant difficulty with accurate thyroglobulin measurement especially in patients with interfering cross reacting antibodies as well as 4 the poor predictive value of a negative assay, which may be associated with up to 10% disease persistence or recurrence on long-term follow-up. 5 A biomarker that is not dependent on active disease status will facilitate the identification of patients at risk prior to disease recurrence thereby providing an early opportunity to alter the course of the disease.
Previous studies showed a strong correlation between the intensity of tumor infiltrating lymphocytes, especially the CD8+ T cell subset, with reduced risk of recurrence in thyroid cancer. [6] [7] [8] Furthermore, patients with hyperactive autoimmune thyroid diseases experienced improved cancer free survival following surgery. 9 These observations suggest an important role for tumor directed immunity in the outcome of this disease. Elucidation of the role of impaired anti-tumor immunity in thyroid cancer recurrence may lead to the identification of novel monitoring biomarkers and novel therapeutic approaches.
Inactivation of effector lymphoid cells within the tumor microenvironment and in the peripheral circulation is a potential mechanism of immune evasion by cancer cells. [10] [11] [12] FAS or CD95 is a member of the death receptor family of proteins and a type I transmembrane receptor normally expressed on activated lymphocytes that is also expressed aberrantly in non lymphoid tissues including cancer cells. 13, 14 It forms a receptor-ligand system with its ligand, FASL or CD95L, and its activation by this ligand triggers apoptotic cell death, a central regulatory mechanism of the immune system. 15 FASL is a membrane bound protein that is cleaved through the proteolytic action of metalloproteinase enzyme, leading to the release of a soluble non membrane-bound fragment, sFASL, which is also capable of receptor binding and triggering apoptotic death of activated T lymphocytes and natural killer cells. 16 This dynamic interaction between FAS and its ligand, whether membrane-bound or soluble, potently modulates the function of activated T cells and is important for the normal regulation of the body immune system. 15 Increased expression of both FAS and FASL was observed on tumor cells exposed to cytotoxic agents indicating a role in cell killing induced by these agents. 16 We expect that changes in cellular, immune and inflammatory cytokine mediators within the tumor microenvironment will induce parallel measurable changes in the peripheral blood circulation. This approach to biomarker identification and application for predictive and prognostic assessment in cancer patients is increasingly being adopted as a discovery tool. A recent study employed a multiplex assay of immunologic markers along with mass spectrometry as a screening modality in a patient population at high risk for lung cancer. Interestingly, soluble FAS was one of the identified biomarkers that accurately classified cancer patients from those with chronic lung disease. 17 Similarly, comprehensive multiplex assay has been used to identify a panel of serum-based angiogenic and inflammatory biomarkers that predict the clinical benefit of sorafenib and pazopanib in renal cancer patients. 18, 19 We therefore hypothesized that proper characterization of changes in the serum-based immunologic and inflammatory biomarker profile may inform a risk-adapted surveillance strategy in thyroid cancer. This cross sectional cohort study was conducted to assess the profile of circulating cellular and cytokine mediators of immunologic and inflammatory function in patients with differentiated thyroid cancer.
Materials and Methods

Patient Recruitment and Blood Sample Collection
This study was conducted under an IRB-approved protocol. Patients previously treated with curative surgery for papillary or follicular thyroid cancer who had suffered disease relapse or were on surveillance follow-up were enrolled between September 2010 and September 2011. Healthy subjects without prior cancer history were recruited using advertisement fliers. Clinical and demographic data were collected from patients but not from healthy volunteers based on the scope of IRB approval. Single time point peripheral blood samples collected from each participant were analyzed by flow cytometry within 4 hours of collection. Simultaneously collected samples for cytokine assay were processed by centrifugation at 1500g and the resultant plasma and serum aliquoted and stored at −80°F until ready for analysis.
Complete Blood Count (CBC) and Multiparameter Flow Cytometry
Flow cytometry and immune function assays were performed in the Flow Cytometry Core laboratory of the Winship Cancer Institute of Emory University (Atlanta, GA). CBC enumeration was performed immediately (generally within 4 hours of sample collection) using Coulter AC*T diff (Beckman Coulter, Miami, Fl). The total WBC count per ml of blood was used to estimate the absolute numbers of the immune cell subsets by FACS analysis.
Flow cytometry was performed using 200-300 L of RBC-lyzed samples. Samples were stained with antibodies against CD3, CD4, CD8, CD69, PD-1, CTLA-4, CD64, PD-L1 and PD-L2 in order to enumerate various subsets of B lymphocytes, T lymphocytes and antigen presenting cells (APC). B lymphocytes were further characterized by staining with antibodies against CD3, CD19, CD38, and CD27. Natural killer (NK) cells were characterized by a panel of antibodies against CD3, CD4, CD94, NKG2A, CD16 and CD56 while regulatory T cells (T-regs) were identified with a panel of antibodies against CD3, CD4, CD25 and Foxp3 along with isotype control after fixation and permeabilization using commercial anti-human Foxp3 Kit (eBioscience, San Diego, CA). The complete list of circulating leukocyte subsets employed for this study is provided in Table 1 .
Immunologic Function Assays
Functional activity of B-cell, T-cell and NK cell subpopulations was assessed by granzyme-B and interferon gamma (IFN-) production with or without PMA/ionomycin stimulation in vitro using a standard assay method. Briefly, peripheral blood mononuclear cells (PBMCs) isolated by Ficoll gradient centrifugation were stimulated with LeuAct cocktail (PMA, Ca, ionomycin and Golgi plug; BD Pharmingen, Boston MA) for 4 hours at 37°C, under 5% CO 2 as recommended by the manufacturer. Thereafter, cells were stained with antibodies against CD3, CD4, CD8, IFN-and granzyme-B. PBMCs treated only with Golgi plug served as an unstimulated control. Appropriate isotype antibodies were included as control to detect nonspecific staining. Functional NK (CD3-CD16+CD56+), CD4+ and CD8+ T cells were estimated by intracellular FACS analysis for the proportion of cells producing IFN-or granzyme-B using Cytofix/Cytoperm™ Solution Kit (BD Biosciences, San Diego, CA).
Luminex Assay
This assay was performed in a blinded fashion at the immunology core lab at Stanford University, (Stanford, CA). Human 51-plex kits were purchased from Affymetrix and used according to the manufacturer's recommendations with modifications as described below. Briefly, samples were mixed with antibody-linked polystyrene beads on 96-well filter plates and incubated at room temperature for 2 hours followed by overnight incubation at 4°C. Plates were vacuum-filtered and washed twice prior to 2-hour incubation with biotinylated detection antibody. Samples were then filtered as above, washed twice and re-suspended in streptavidin-PE. After incubation for 40 minutes at room temperature, two additional vacuum washes were performed, and the samples resuspended in Reading Buffer. All samples were assayed in a single batch and each sample was measured in duplicate. Plates were read using a Luminex 200 instrument with a lower bound of 100 beads per sample per cytokine. A complete list of the Affymetrix Human 51-plex cytokines is detailed in Table 1 .
Statistics
The primary outcome measure was progression free survival (PFS) measured from the date of initial surgery. Depending on whether the data satisfied the assumption of normal distribution, t-test or Wilcoxon rank-sum test was employed to examine differences in the mean biomarker level between defined subgroups based on disease status and gender. Spearman or Pearson correlation coefficients were estimated to measure the relationship between biomarker and clinical covariates. Significant correlations were established by Wald's test. Univariate association of each biomarker with PFS for patient subgroups was determined by Cox regression analysis. In multivariable survival analyses, best model selection using the backward selection method started with biomarkers and clinical covariates that achieved statistical significance (p≤0.1) in the univariate analyses. Survival curves and estimate of the survival rate associated with each specific biomarker of interest (stratified by >median vs. ≤median) were performed according to the Kaplan Meier method and compared by Logrank test.
Receiver operating characteristic (ROC) analyses were performed for biomarkers that showed significant association with PFS in multivariate analysis. The optimal biomarker level that best discriminates patients' disease recurrence status was determined by measuring the area under the curve (AUC) of ROC curves and differences in AUCs of ROC curves were tested with Chi-Square tests. The cut-off values needed to obtain 90% sensitivity and 90% specificity levels in the ROC curves were estimated. To obtain the optimal cut-off points to achieve the maximum sum of sensitivity and specificity for each biomarker with the best discrimination power for disease recurrence, sensitivity and specificity pairs were obtained in the logistic regression under all the possible thresholds. Subsequent validation of the cut-off values estimated by ROC analysis was performed using an outcome-oriented optimal cut-point determination (OCD) algorithm according to the method of Contal & O'Quigley. 20 PFS curves were generated for the two groups stratified by the optimal cut-off value estimated by ROC and OCD methods; significance of differences in PFS was assessed by Logrank test.
The SAS statistical package V9.2 (SAS Institute, Inc., Cary, North Carolina) was used for data management and analyses.
Results
Clinical Data Analysis
A total of 35 patients with differentiated thyroid cancer and 21 healthy volunteers were enrolled on this study. Median age of the patients was 49 years; 24 (69%) were females and 11 (31%) were males. There were 6 patients (17%) with follicular cancer, 28 (80%) with papillary and 1 patient (3%) with poorly differentiated thyroid cancer. Fifteen patients (43%) already had disease recurrence at the time of enrollment. The median time to recurrence following initial surgery for all patients was 5.3 years (1.6 years for patients with recurrence). Three patients had died at the time of data cut-off for analysis at a median follow-up time post surgery of 6.7 years; 6.2 years versus 8.2 years for patients without and with established recurrence, respectively. None of the healthy volunteers reported any current or prior history of cancer.
Comparison between patients with and without disease recurrence-Univariate
analysis of association between PFS and clinical prognostic factors for thyroid cancer (age, tumor size, biochemical recurrence, locoregional and distant metastasis) showed a trend in the expected direction in the study population ( Table 2) .
Biomarker Analysis
Comparison of biomarker levels between patients and healthy control-There were significant differences between thyroid cancer patients and healthy controls in 17 of 51 cytokines tested. Leptin and ICAM1 showed the greatest difference with a 4-fold or more increase in level in patients compared with healthy subjects ( Table 3) .
Comparison of biomarkers between the two patient subgroups showed higher levels of CD40Ligand, sFASL and TGF-beta as well higher numbers of leukocyte subsets with PD-1, PD-L1 or CTLA4 surface expression in patients without recurrence (Table 4 ). Functional assay showed a non significant trend of higher IFN-response to PMA stimulation in patients without disease recurrence (data not shown).
Univariate analysis and multivariate analyses of biomarker impact on survival
-G-CSF, IL-12P40, PAI-1, sFASL, TGF-b, PD-1+CD4, PD-1+CD8, CD64+PD-L1+ showed a significant association with PFS on univariate analysis while TGF-, PAI-1, sFASL, IFN-and PD-1+CD8+ cell subsets maintained a significant association with PFS on multivariate analysis. Only sFASL and IFN-showed a significant association with PFS on multivariate analysis that incorporated significant biomarkers and clinical variables identified from the univariate analyses (Table 2) . Consistent with this association, patients with disease progression as measured by the PFS from the time of original surgery had a statistically significant lower level of sFASL in circulation than patients without disease recurrence. The differences in median IFN-levels based on cancer recurrence status of the patients did not reach statistical significance ( Table 5 and Figure 1 ). There was no significant correlation between sFASL and age of the subjects (data not shown).
ROC Analysis and Optimal Cut-point Determination
ROC analysis estimated sFASL level of 15.001 pg/ml and IFN-level of 2.7105 pg/ml as the optimal values for stratifying patients to predict recurrence (Figure 2 ) while the OCD method estimated the optimal values as 15.11pg/ml for sFASL and 5.17pg/ml for IFN-. There was a significant difference in PFS between patient groups separated by the optimal sFASL cut-point value of 15.11pg/ml (Logrank p=0.0009; Figure 3A ) but a marginally significant difference with the values for IFN-(2.7105 pg/ml; Logrank p=0.0885 and 5.17pg/ml; p= 0.0817; Figure 3B and 3C).
Discussion
The potential role of host immune function in thyroid cancer outcomes has been previously demonstrated, [6] [7] [8] [9] but this is the first study to evaluate a comprehensive panel of immunerelated biomarkers in thyroid cancer patients. The comparison between patients and controls revealed higher levels of leptin and ICAM-1 in patients. Our findings are consistent with those of previous studies that showed significantly higher levels of leptin in thyroid cancer patients relative to control subjects and a significant drop in serum leptin levels following surgical resection of thyroid cancer. 21, 22 Intriguingly, high leptin levels were shown to portend an aggressive disease course in breast and prostate cancer, [23] [24] [25] [26] [27] and an altered leptin signaling network in concert with the PI3K/Akt signaling pathway plays a role in thyroid cancer development. 28, 29 However, we did not establish a significant difference in leptin levels between patients with or without disease recurrence, perhaps due to the small number of patients.
In order to identify novel immune-related biomarkers that may predict thyroid cancer recurrence, we adopted a stepwise comparison of the biomarkers of interest in patients with and without disease. This stringent approach enabled us to identify the most robust biomarker. We identified a significant association of low sFASL and high IFN-with thyroid cancer recurrence. The finding of low sFASL levels in patients with thyroid cancer recurrence is consistent with the work by Hoffman et al., who also observed lower levels of sFASL in patients with active head and neck cancer relative to patients without disease recurrence or normal controls. 10 Other investigators have, however, reported the contrary finding of high sFASL levels correlating with advanced disease. [30] [31] [32] [33] The biology and function of sFASL remains controversial and the blood level of sFASL partly reflects a dynamic balance between its aberrant production by cancer cells and clearance from the circulation through the scavenger role of aberrant FAS receptor. Signaling abnormalities and increased apoptosis of effector lymphocytes occur in cancer patients leading to immune evasion by cancer cells. 11, 12, 34 This phenomenon was previously demonstrated in patients with lymphoid and gastrointestinal malignancies but has not yet been found in thyroid cancer. 35 It results from apoptosis of tumor infiltrating lymphocytes induced by membrane FASL on tumor cells and of peripheral circulating lymphocytes by sFASL away from the tumor sites. 11, 12, 34 Such a model would predict higher sFASL to be associated with higher risk of cancer recurrence. While the biological impact of sFASL in thyroid cancer remains to be fully elucidated, prior studies showed that FAS and FASL are expressed in thyroid cancer, but normal and neoplastic cells of thyroid lineage are intrinsically resistant to FASmediated apoptosis. 36 Indeed, homotrimerization of the FAS receptor by exogenous agonistic antibody induced a paradoxical cellular proliferation rather than apoptosis. 37, 38 Intriguingly, the same thyroid cell lines were susceptible to apoptosis induced by TRAIL, a related member of the TNF superfamily. 37, 38 Alternatively, since activated lymphocytes constitute a major source of sFASL in circulation, it is plausible that sFASL in thyroid cancer patients arises from the proteolytic cleavage of expressed FASL on activated immune effector cells. This model would suggest that, contrary to the observation in some cancer types, thyroid cancer patients with high levels of sFASL have activated immune competent cells and an effective immune surveillance network that delays or prevents disease recurrence. Consistent with this explanation, elevated sFASL was detected in patients with hyperactive immune function such as hyperthyroid Graves's disease and idiopathic myocarditis; [39] [40] [41] clinical conditions associated with good prognosis in thyroid cancer patients.
Our findings set the table for important future clinical applications such as disease monitoring or prognostication post surgery and provide novel testable hypotheses in thyroid cancer patients. Our discovery goal was aided by the ability to interrogate a large panel of serum-based cytokines from a small volume of blood using the Luminex assay platform. Nonetheless, we recognize some important limitations of the study including the modest sample size and the fact that we only performed a single time point assessment at varying periods post surgery. Despite these limitations, our results provide a useful benchmark on which to build much larger prospective studies to further characterize and validate the predictive and prognostic importance of sFASL in thyroid cancer. Summary of the ROC analyses for optimal sensitivity and specificity of sFASL and IFN- Kaplan Meier curve of PFS for patients with differentiated thyroid cancer. NB: The analyzed data included a single patient diagnosed with thyroid cancer in childhood who was without disease recurrence for more than 40 
